Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Prof. Dr. Annette Kopp-Schneider

Prof. Dr. Annette Kopp-Schneider

Prof. Dr. Annette Kopp-Schneider


Head of Division


+49 6221 42 2391


+49 6221 42 2397


TP 4




  • Diploma in Mathematics, RWTH Aachen, Germany, 1984
  • Dr. rer. nat., Mathematics, RWTH Aachen, Germany, 1987
  • Habilitation, Medical Biometry, University Heidelberg, 1997


Areas of Work

  • Clinical trials for precision oncology
  • Dose response modelling
  • Biological based mechanistic modelling of cell systems


Selected Publications

van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, ... Kopp-Schneider A, Jones DTW, Molenaar JJ, Capper D, Pfister SM, Witt O. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021 Nov;11(11):2764-2779. doi: 10.1158/2159-8290.CD-21-0094.

Wiesenfarth M, Reinke A, Landman BA, Eisenmann M, Saiz LA, Cardoso MJ, Maier-Hein L, Kopp-Schneider A. (2021) Methods and open-source toolkit for analyzing and visualizing challenge results. Sci Rep. 11(1):2369. doi: 10.1038/s41598-021-82017-6.

Zocholl D, Wiesenfarth M, Rauch G, Kopp-Schneider A. On the feasibility of pediatric dose-finding trials in small samples with information from a preceding trial in adults. J Biopharm Stat. 2021 Online ahead of print. doi: 10.1080/10543406.2021.2011905.

Maier-Hein L, Reinke A, Kozubek M, Martel AL, Arbel T, Eisenmann M, Hanbury A, Jannin P, Müller H, Onogur S, Saez-Rodriguez J, van Ginneken B, Kopp-Schneider A, Landman BA. (2020) BIAS: Transparent reporting of biomedical image analysis challenges. Med Image Anal. 66:101796. doi: 10.1016/

Kopp-Schneider A, Calderazzo S, Wiesenfarth M. (2020) Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control. Biom J.;62(2):361-374..doi: 10.1002/bimj.201800395

Calderazzo S, Tavel D, Zurich MG, Kopp-Schneider A. (2019) Model-based estimation of lowest observed effect concentration from replicate experiments to identify potential biomarkers of in vitro neurotoxicity. Arch Toxicol. 93(9):2635-2644.. doi: 10.1007/s00204-019-02520-8

Maier-Hein L, Eisenmann M, ..., Jannin P, Kopp-Schneider A. Why rankings of biomedical image analysis competitions should be interpreted with care. Nat Commun. 2018 Dec 6;9(1):5217. doi: 10.1038/s41467-018-07619-7

Kopp-Schneider A, Wiesenfarth M, Witt R, Edelmann D, Witt O, Abel U. (2019) Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach. Biom J. 61: 488-502. doi: 10.1002/bimj.201700209

Holland-Letz T, Gunkel N, Amtmann E, Kopp-Schneider A. (2018) Parametric modelling and optimal experimental designs for estimating isobolograms for drug interactions in toxicology. J Biopharmaceut Stat 28(4):763-777. doi: 10.1080/10543406.2017.1397005

Habermehl C, Benner A, Kopp-Schneider A. (2018) Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction. Biom J. 60(2):275-287. doi: 10.1002/bimj.201600226

Holland-Letz T, Kopp-Schneider A. (2018) Optimal experimental designs for estimating the drug combination index in toxicology. Computational Statistics and Data Analysis 117: 182–193. doi: 10.1016/j.csda.2017.08.006

Jiang X., Kopp-Schneider A. (2014) Summarizing EC50 estimates from multiple dose-response experiments: a comparison of a meta-analysis strategy to a mixed-effects model approach. Biom J. 56(3), 493-512. doi: 10.1002/bimj.201300123


to top
powered by webEdition CMS